Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Ellen McLaughlin

BMS CEO optimistic re future of medical research

Giovanni Caforio, chairman and CEO of Bristol Myers Squibb, was recently interviewed in Fortune: “If there is any good news coming out of the coronavirus pandemic, it’s...

| By Ellen McLaughlin

Biohaven and Arvinas add to Board of Directors

Biohaven reports the appointment of pharmaceutical industry leader Robert J. Hugin to its board of directors, effective immediately. Hugin previously was chairman and chief executive officer...

| By Ellen McLaughlin

P2 Science closes $3 million line of credit

P2 Science has closed on a $3 million line of credit with Webster Bank. The company, which has a manufacturing plant in Naugatuck and research...

| By Ellen McLaughlin

BIO Digital sessions now available on demand

Last week at BIO Digital, Dr. Michelle McMurry-Heath, BIO’s President & CEO, moderated the panel “Leading Through Crisis: Speaking Up and Out on Equity, Diversity,...

| By Ellen McLaughlin

Azitra moves to Branford to accommodate growth

Azitra has opened its new 12,000 square foot laboratory and office complex in Branford, CT. Previously operating out of three small labs located at the...

| By Ellen McLaughlin

CT medical marijuana program to treat chronic pain

The Connecticut Legislature’s Regulations Review Committee has approved two new conditions to allow patients with chronic pain and an inherited disorder that affects the body’s...

| By Ellen McLaughlin

Dementia gene raises risk of severe COVID-19

Having a faulty gene linked to dementia doubles the risk of developing severe COVID-19, according to a large-scale study. Researchers at the University of Exeter...

| By Ellen McLaughlin

Genetic-based precision medicine holds promise

A type of personalized care known as precision medicine, and its subset, genomic medicine, is now the standard of care in Connecticut’s Hartford HealthCare Cancer Institute, UConn...

| By Ellen McLaughlin

BioCT stands with BLM

“Black Lives Matter and BioCT is committed to addressing racism through members’ employment practices, their development of therapeutics to benefit all patients and our support of...

| By Ellen McLaughlin

Pfizer establishes new innovation program

Pfizer is establishing the Pfizer Breakthrough Growth Initiative, through which Pfizer will invest up to $500 million in biotechnology companies to help provide funding and...